Genmab — December 2012
-
Genmab will discuss daratumumab and ofatumumab data presented at the 2012 Annual Meeting of the American Society of Hematology (Dec. 8-11), plus other products and updates on our proprietary technologies on Dec. 17 at 2PM GMT / 3PM CET / 9AM EST.
-
update på duobody. Det er jo ikke fordi markedet har lagt så meget ind i kursen på de mange milliard potentielle duobody indikationer. Så han må meget gerne give lidt input til os der
-
lidt kryptisk har man lov at være. Det betyder at jeg tror at kursen er højere den 18. dec. end den er den 17
-
ja, men jeg vil rigtigt rigtigt gerne høre noget firm guidance på fiscal
-
det drømmer mit akademiker hjerte om
-
vi skal have noget fast bra
ndstof. I need milestones visibility -
nej desværre
Hi Peter, it is focused on clinical, preclinical and technology updates. -
så det bliver for biotek nørderne
-
svar fra altid hurtige Rachel i IR på dette spørgsmål
-
What should we expect to hear next monday?
Is it only clinical discussion and progress on the pipeline as one should expect from a Post - ASH seminar or will there be given any updates of a more fiscal nature?
- Will there be visibility concerning the milestones structure of Daratumumab?
- Will there be visibility concerning the milestones structure of the numerous duobody deals?
- Will there be given any other fiscal updates ?
-
så jeg gik forgæves
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind